GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHF) » Definitions » Cyclically Adjusted PS Ratio

Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Cyclically Adjusted PS Ratio : 1.63 (As of Jun. 18, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Cyclically Adjusted PS Ratio?

As of today (2024-06-18), Sihuan Pharmaceutical Holdings Group's current share price is $0.065. Sihuan Pharmaceutical Holdings Group's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 was $0.04. Sihuan Pharmaceutical Holdings Group's Cyclically Adjusted PS Ratio for today is 1.63.

The historical rank and industry rank for Sihuan Pharmaceutical Holdings Group's Cyclically Adjusted PS Ratio or its related term are showing as below:

SHPHF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.46   Med: 4.83   Max: 20.86
Current: 1.58

During the past 13 years, Sihuan Pharmaceutical Holdings Group's highest Cyclically Adjusted PS Ratio was 20.86. The lowest was 1.46. And the median was 4.83.

SHPHF's Cyclically Adjusted PS Ratio is ranked better than
60.7% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs SHPHF: 1.58

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sihuan Pharmaceutical Holdings Group's adjusted revenue per share data of for the fiscal year that ended in Dec23 was $0.028. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.04 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sihuan Pharmaceutical Holdings Group Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Cyclically Adjusted PS Ratio Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.60 2.24 3.87 2.56 1.83

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.87 - 2.56 - 1.83

Competitive Comparison of Sihuan Pharmaceutical Holdings Group's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sihuan Pharmaceutical Holdings Group's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Cyclically Adjusted PS Ratio falls into.



Sihuan Pharmaceutical Holdings Group Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sihuan Pharmaceutical Holdings Group's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.065/0.04
=1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sihuan Pharmaceutical Holdings Group's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Sihuan Pharmaceutical Holdings Group's adjusted Revenue per Share data for the fiscal year that ended in Dec23 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=0.028/114.7809*114.7809
=0.028

Current CPI (Dec23) = 114.7809.

Sihuan Pharmaceutical Holdings Group Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.048 99.000 0.056
201512 0.047 100.600 0.054
201612 0.045 102.600 0.050
201712 0.044 104.500 0.048
201812 0.045 106.500 0.048
201912 0.043 111.200 0.044
202012 0.040 111.500 0.041
202112 0.050 113.108 0.051
202212 0.034 115.116 0.034
202312 0.028 114.781 0.028

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sihuan Pharmaceutical Holdings Group  (OTCPK:SHPHF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sihuan Pharmaceutical Holdings Group Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Business Description

Traded in Other Exchanges
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.